Tarsus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Tarsus Pharmaceuticals

10/08/2023 22:32

* Tarsus Pharmaceuticals Inc  TARS.OQ  reported a quarterly
adjusted loss of $1.17​​ per share for the quarter ended in
June. The mean expectation of seven analysts for the quarter was
for a loss of $1.08 per share.
    * Reported revenue was zero​; analysts expected $1.76
million. 
    * Tarsus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.17​.
    * The mean earnings estimate of analysts had fallen by
about 5.1%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates 
    * Tarsus Pharmaceuticals Inc shares had fallen by 4.5% this
quarter and gained 17.7% so far this year.
    * The company reported a quarterly loss of $31.42 million.
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $50.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 09:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -1.08          -1.17          Missed
 Mar. 31 2023      -0.94          -0.88          Beat
 Dec. 31 2022      -0.69          -0.49          Beat
 Sep. 30 2022      -0.97          -0.84          Beat